Current Report Filing (8-k)
09 November 2021 - 12:10AM
Edgar (US Regulatory)
0001012477
false
0001012477
2021-11-08
2021-11-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of report
(Date of earliest event reported): November 8, 2021
AVADEL PHARMACEUTICALS PLC
(Exact Name of Registrant as Specified
in its Charter)
|
Ireland
|
001-37977
|
98-1341933
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
|
10 Earlsfort Terrace
Dublin 2, Ireland, D02 T380
|
Not Applicable
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code: +353 1 901 5201
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
American Depositary Shares*
Ordinary Shares, nominal value
$0.01 per share**
|
AVDL
N/A
|
The Nasdaq Global Market
|
*American Depositary Shares may be evidenced by American Depositary
Receipts. Each American Depositary Share represents one (1) Ordinary Share.
** Not for trading, but only in connection with the listing
of American Depositary Shares on The Nasdaq Global Market.
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
|
Item
2.02
|
Results
of Operations and Financial Condition
|
On November 8, 2021, Avadel Pharmaceuticals plc announced its
financial results for the quarter ended September 30, 2021. A copy of the press release is being furnished as Exhibit 99.1 to
this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AVADEL PHARMACEUTICALS PLC
|
|
|
|
|
|
Date: November 8, 2021
|
By:
|
/s/ Jerad G. Seurer
|
|
|
Name:
|
Jerad G. Seurer
|
|
|
Title:
|
Vice President, Legal Affairs & Corporate Secretary
|
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2023 to Apr 2024
